February 14, 2005Proceedings of the National Academy of SciencesOpen Access

Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice

View Full Paper

Ask AI

Bookmark

Why the study?

Does NO-1886 reduce hyperlipidemia and intestinal polyp formation in Apc-deficient Min mice?

Structured PICO

Does NO-1886 reduce hyperlipidemia and intestinal polyp formation in Apc-deficient Min mice?

Population

Min mice (Apc-deficient mice) starting at 7 weeks of age

Intervention

NO-1886 at 400 and 800 ppm in the diet for 13 weeks

Comparator

Untreated control diet

Outcome

Serum lipid levels (triglycerides, VLDL, LDL, HDL) and total numbers of intestinal polypssurrogate

NO-1886 suppresses hyperlipidemia and intestinal polyp formation in Apc-deficient Min mice, suggesting potential utility as a chemopreventive agent for colon cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports polyp reduction via triglyceride lowering in Min mice; leaves open human chemopreventive translation.

Cite This Study

Niho et al. (2005) studied this question.

synapsesocial.com/papers/6a85a31aa46f793aa75e35b8 https://doi.org/10.1073/pnas.0500153102

View Full Paper

Ask AI

Bookmark